Industry News

Immune Therapeutics, Inc., a clinical-stage pharmaceutical company focused on the commercialization and development of the first affordable non-toxic immunodulator for the treatment of inflammatory diseases, immune-related disorders, and cancer, today announces the appointment of two new members to its Medical and Clinical Advisory Board comprised of: Joseph M. Chalil, MD and Mak Jawadekar, Ph.D., join Clifford A. Selsky,..."/>
Immune Therapeutics, Inc. Announces Appointments to its Medical and Clinical Advisory Board
Capricor Therapeutics, Inc. today announced the closing of its previously announced underwritten registered public offering and concurrent registered direct offering. In the registered public offering, a total of 3,090,625 shares of the Company's common stock were sold at an offering price of $3.20 per share. The shares include 403,125 shares of common stock sold pursuant to the underwriters' over-allotment option, which option was..."/>
Capricor Therapeutics Announces Closing of Public Offerings Raising Approximately $10.0 Million in Net Proceeds
UnitedHealth Group’ s free-standing pharmacy care services business, is adding 120 pharmacy customer service representative jobs in Costa Mesa. These new customer service positions, including bilingual customer service roles, will support the pharmacy benefit needs of OptumRx members and help deliver better health care experiences."/>
OptumRx Recruiting for 120 New Customer Service Jobs in Costa Mesa
Medovex Corp., a developer of medical technology products, today announced that the Company will exhibit during EuroSpine which is being held from October 5-7, 2016 in Berlin, Germany. As part of the product exhibition, Medovex will highlight its innovative DenerveX™ System, a minimally invasive surgical procedure pioneered by Medovex that was built around the combination of denervation and capsulectomy with reproducible results, "A potential paradigm..."/>
Medovex Corporation to Demonstrate Expanding EMEA Business During EuroSpine 2016, Berlin, Germany
BiondVax Pharmaceuticals Ltd. announced today that the last participant in a European Phase 2 b clinical trial of M-001, its universal flu vaccine candidate, has completed their final visit. Conducted in collaboration with the EU-sponsored UNISEC consortium, the trial is designed to evaluate the safety and immunogenicity of M-001 when used ahead of a pandemic influenza vaccine. "This important milestone marks the conclusion of the patient facing part of..."/>
BiondVax Phase 2b European Trial: Last Patient Out; Top line results expected in the coming months
EyeGate Pharmaceuticals, Inc.,, a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that Stephen From, President& Chief Executive Officer of EyeGate, is scheduled to present at the 2016 Aegis Capital Corp. Investment Growth Conference, being held September 21 and 22, 2016 at the Encore at Wynn Las Vegas in Las Vegas, NV. Details of the presentations are as follows:."/>
EyeGate Pharmaceuticals to Present at the 2016 Aegis Capital Conference
Cerecor Inc., a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has completed patient enrollment in its Phase 2 clinical trial for CERC-301, Clin301-203, as an oral, rapidly acting adjunctive treatment of major depressive disorder. The Company now expects to report top-line data from this..."/>
Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder
GVC Holdings hit an all-time high after it reported a 12 pc increase in revenue. The highest riser on the FTSE 350 for the day, the firm behind brands such as Foxy Bingo, said revenue in the six months to June 30 was pounds sterling 327.5 m. Pre-tax profit more than doubled from a year ago to pounds sterling 44 m."/>
Daily Mail, London, market report column [Daily Mail, London]
Daily Mail, London, Alex Brummer column [Daily Mail, London]
Aegerion Pharmaceuticals disclosed on Tuesday the appointment of Remi A. Menes as chief commercial officer, effective immediately. Most recently, Menes has served as the board member of Pharma Industry Finland as well as general manager of AbbVie Finland, which he joined in 2013,. Menes previously worked as area commercial director, Virology& Neonatal Care, Western Europe& Canada at AbbVie Europe as well as commercial director, Specialty Products..."/>
Aegerion Pharmaceuticals names Remi Menes as chief commercial officer
MRI Interventions, Inc. today announced that its ClearPoint Neuro Navigation System will be utilized at a Practical Clinic entitled“ Laser Ablation Surgery: Opportunities, Indications, Technique and Outcomes” during the Congress of Neurological Surgeons taking place on September 24- 28, 2016, in San Diego, California. Both the lecture and hands-on workshop will focus on the underlying principles of real-time, image guided laser ablation for..."/>
MRI Interventions’ ClearPoint® Neuro-Navigation System to be Featured at the Congress of Neurological Surgeons (“CNS”), in a Hands-On Workshop Entitled, “Laser Ablation Surgery Practical Clinic”
CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the pricing of its public offering of 2.25 million shares of its common stock at a price to the public of $4.00 per share. In addition, the Company has granted the underwriters a 30- day option to purchase up to 337,500 additional shares of..."/>
CareDx Announces Pricing of Public Offering of Common Stock
Thermo Fisher Scientific Inc revealed on Tuesday that it has completed the acquisition of FEI Company for a purchase price of USD107.50 per share in cash, or a total purchase price of approximately USD4.2bn. FEI Company Inc is a provider of high-performance electron microscopy business and will now become part of Thermo Fisher's Analytical Instruments Segment. Upon completion and by year three, TMO expects to realize total synergies of about USD80m."/>
Thermo Fisher Scientific acquires FEI Company for USD4.2bn
BioMarin Pharmaceutical Inc. today announced that it intends to seek a review of the Patent Trial and Appeal Board of the United States ruling in Interference No. 106,008, related to composition of matter claims related to exon 51 skipping antisense oligonucleotides."/>
BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics
NeuroMetrix on Tuesday announced it plans to increase the availability of Quell Wearable Pain Relief Technology to veterans who suffer from chronic pain through the Veterans Health Administration. According to the company, it has successfully completed its registration process in the US federal government's System for Award Management, a requirement for selling products to any federal government entity including the Veterans Health..."/>
NeuroMetrix to expand availability of Quell Wearable Pain Relief Technology via the Veterans Health Administration
Agios Pharmaceuticals reported on Tuesday the completion of its public offering of 3,876,403 common stock at a price of USD44.50 per share. This public offering including the exercise in full by the underwriters of their option to purchase an additional 505,617 shares at the same public offering price. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Agios to 3,876,403..."/>
Agios concludes public offering at USD44.50 per share
BiondVax Pharmaceuticals Ltd. announced today that the last participant in a European Phase 2 b clinical trial of M-001, its universal flu vaccine candidate, has completed their final visit. Conducted in collaboration with the EU-sponsored UNISEC consortium, the trial is designed to evaluate the safety and immunogenicity of M-001 when used ahead of a pandemic influenza vaccine."/>
BiondVax Phase 2b European Trial: Last Patient Out
Ensign Group declared on Tuesday that it will pay a quarterly dividend of USD0.04 per share of its common stock. Shareholders of record as of 30 September 2016 will receive the cash dividend on or before 31 October 2016.. According to the home health care company, it has been paying dividends since 2002.."/>
The Ensign Group reports USD0.04 per share dividend
Integra LifeSciences Holdings reported on Tuesday that the first three procedures using the Integra Cadence total ankle system have been completed in Europe. The ankle surgeries were carried out by Dr Thibaut Leemrijse of the Foot and Ankle Institute, Parc Lopold Clinic, Brussels, Belgium. Following the European launch of the Cadence system, the company's new improved designs as well as advanced surgical education programmes are fueling the growth of the..."/>
Integra LifeSciences reports first three surgical procedures with Cadence total ankle system in Europe
Neuralstem, Inc., a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced that it has reached over 50% enrollment in its Phase 2 clinical trial evaluating NSI-189, a novel neurogenic small molecule, for the treatment of major depressive disorder.. The ongoing Phase 2 MDD study is testing two doses of NSI-189, a small molecule in an oral tablet formulation."/>
Neuralstem Achieves 50% Enrollment in NSI-189 Phase 2 Trial in Major Depressive Disorder
Hemostemix Inc., a clinical-stage autologous cell-therapy company, announces today that it has successfully completed the annual re-certification of its Israeli manufacturing site and lab facility. The re-certification complies with the cGMP standards for manufacturing of biological products for use in humans and fulfills the requirements of the US-FDA and other international health authorities. The re-certification was conducted by QCC..."/>
Hemostemix Announces Successful Re-Certification of its Israeli Manufacturing Facility
Keryx Biopharmaceuticals, Inc,, a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast its corporate presentation at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27 at 4:00 p.m. Eastern Time.. A live audio webcast of the presentation will be accessible from Keryx’ s website at http://investors.keryx.com within the Investor Relations section under“..."/>
Keryx Biopharmaceuticals to Webcast its Presentation at Ladenburg Thalmann’s 2016 Healthcare Conference

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology633 Articles
Consumer Discretionary556 Articles
Financials344 Articles
Industrials343 Articles
Health Care323 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.